1-Palmitoyl-2-hydroxy-sn-glycero-3-phosphoinositol (LysoPI, 16:0 LPI) is a synthetic, purified palmitoyl PI. Lysophospholipids are lipid mediators which elicit a diverse array of cellular responses through activation of phospholipid specific G protein-coupled receptors. Lysophosphatidylinositol (LPI) induces a number of cellular effects through binding to the GPR55 receptor including angiogenesis, bone morphogenesis, cancer progression and pain. In addition LPI is thought to be a biomarker for certain cancers.
Storage
-20 C or below
References
1) K. Makide, et al ''Novel lysophosphoplipid receptors: their structure and function Journal of Lipid Research, 2014, 55, 1986. 2) J.M. Moreno-Navarette, et al. ''The l-a-Lysophosphatidylinositol/GPR55 System and Its Potential Role in Human Obesity Diabetes, 2012, 61, 281-291. 3) M. Falasca & R. Ferro. ''Role of the lysophosphatidylinositol/GPR55 axis in cancer Advances in Biological Regulation, 2016, 60, 88-93.
